Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Ciprofloxacin Tablets

Ciprofloxacin Tablets

NAFDAC REG NO: C4-1545 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 1 November 2026 · synced automatically from official sources.
Produit
Ciprofloxacin Tablets
Numéro NAFDAC
C4-1545
Principe actif
Ciprofloxacin (Ciprofloxacin Hydrochloride)
Dosage
500 mg
Forme
Tablet
Conditionnement
1 x 10's (in blister)
Fabricant
Non répertorié
Déposant / Titulaire :
Med-Long Pharmaceutical & Chemical Co Ltd
Approuvé
28 Jan 2021
Statut
Inactive Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
27 Jan 2026
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Ciprofloxacin: uses, dosage and brands worldwide

What we found

  • Ciprofloxacin Tablets is on the NAFDAC register with an active registration (C4-1545). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Ciprofloxacin Tablets

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.

Comment le prendre et à quelle fréquence
  • Corneal Ulcers: The recommended dosage regimen
  • For the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day
  • On the second day, instill two drops in the affected eye hourly
  • On the third through the fourteenth day, place two drops in the affected eye every four hours
  • Treatment may be continued after 14 days if corneal re-epithelialisation has not occurred
  • Bacterial Conjunctivitis: The recommended dosage regimen
  • For the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days
Children
  • The safety and effectiveness of Ciprofloxacin ophthalmic solution 0.3% have been established in all ages
  • Use of Ciprofloxacin ophthalmic solution is supported by evidence from adequate and well controlled studies of Ciprofloxacin ophthalmic solution
  • In adults, children and neonates [ see Clinical Studies ]. …
Older adults

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

While you are taking it

Do not touch dropper tip to any surface, as this may contaminate the solution.

Talk to a doctor first if
  • A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use
  • A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin
Medicines it may not mix with

Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Warnings

NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. …

Effets secondaires possibles

The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients ( see Precautions ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision. …

If you take too much

A topical overdose of ciprofloxacin Ophthalmic Solution may be flushed from the eye(s) with warm tap water.

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2022-05-02.

Label for ciprofloxacin (ciprofloxacin hydrochloride), the active ingredient registered with NAFDAC.

Check your pack of Ciprofloxacin Tablets

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Sources officielles : FDA américaine · EMA (UE) · NAFDAC · alertes OMS

About Ciprofloxacin Tablets

What is in Ciprofloxacin Tablets?

Ciprofloxacin Tablets contains Ciprofloxacin (Ciprofloxacin Hydrochloride) (500 mg), as tablet, according to its NAFDAC registration record.

Is Ciprofloxacin Tablets registered with NAFDAC?

Yes. Ciprofloxacin Tablets is listed on the NAFDAC register under registration number C4-1545, and its registration is active as of 1 November 2026.

Has Ciprofloxacin Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Ciprofloxacin Tablets in our automatically synced alert list.

How can I check that my pack of Ciprofloxacin Tablets is genuine?

Run a free authenticity scan with the NAFDAC number C4-1545, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Ciprofloxacin Tablets?

Follow your prescription or the leaflet in your pack. The official label says: Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in th…

What is Ciprofloxacin Tablets used for?

Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aure (Summarised from the official U.S. FDA label for ciprofloxacin (ciprofloxacin hydrochloride). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Ciprofloxacin Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.